Anti-CD20 (rituximab) treatment improves atopic eczema
D Simon, S Hösli, G Kostylina, N Yawalkar… - Journal of Allergy and …, 2008 - Elsevier
BACKGROUND: Atopic eczema (AE) is a chronic inflammatory skin disorder characterized
by eczematous skin lesions, pruritus, and typical histopathological features. OBJECTIVE: We
asked whether depletion of B cells by monoclonal anti-CD20 antibody therapy (rituximab)
would improve severe AE. METHODS: Six patients (4 women and 2 men) with severe AE
received 2 intravenous applications of rituximab, each 1000 mg, 2 weeks apart. To evaluate
the efficacy of rituximab, we monitored clinical parameters (eczema area and severity index …
by eczematous skin lesions, pruritus, and typical histopathological features. OBJECTIVE: We
asked whether depletion of B cells by monoclonal anti-CD20 antibody therapy (rituximab)
would improve severe AE. METHODS: Six patients (4 women and 2 men) with severe AE
received 2 intravenous applications of rituximab, each 1000 mg, 2 weeks apart. To evaluate
the efficacy of rituximab, we monitored clinical parameters (eczema area and severity index …